Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson’s disease
- Autores
- Crispo, James A. G.; Farhat, Nawal; Fortin, Yannick; Pérez Lloret, Santiago; Sikora, Lindsey; Morgan, Rebecca L.; Habash, Mara; Gogna, Priyanka; Shannon E. Kelly; Elliott, Jesse; Kohen, Dafna E.; Bjerre, Lise M.; Mattison, Donald R.; Hessian, Renée C.; Willis, Allison W.; Krewski, Daniel
- Año de publicación
- 2024
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Fil: Crispo, James A. G. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; Canadá
Fil: Farhat, Nawal. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; Canadá
Fil: Fortin, Yannick. University of Ottawa. McLaughlin Centre for Population Health Risk Assessment; Canadá
Fil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina. Observatorio de Salud Publica; Argentina
Fil: Sikora, Lindsey. University of Ottawa. Health Sciences Library; Canadá
Fil: Morgan, Rebecca L. McMaster University. Department of Health Research Methods, Evidence, and Impact; Canadá
Fil: Habash, Mara. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; Canadá
Fil: Gogna, Priyanka. Queen's University. Department of Public Health Sciences; Canadá
Fil: Kelly, Shannon E. University of Ottawa. Faculty of Medicine; Canadá.
Fil: Elliott, Jesse. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; Canadá
Fil: Kohen, Dafna E. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; Canadá
Fil: Bjerre, Lise M. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; Canadá
Fil: Mattison, Donald R. Risk Sciences International; Canadá
Fil: Hessian, Renée C. University of Ottawa. University of Ottawa Heart Institute; Canadá
Fil: Willis, Allison W. University of Pennsylvania. Perelman School of Medicine. Department of Neurology; Estados Unidos
Fil: Krewski, Daniel. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; Canadá
Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson’s disease (PD). The objectives of our review were to evaluate the risk of heart failure and other adverse cardiovascular reactions in PD patients who received a non-ergot DA compared with other anti-PD pharmacological interventions, placebo, or no intervention. Studies were identified via searches of six bibliographic databases. Randomized controlled trials (RCTs) and non-randomized studies (NRS) were eligible for study inclusion. Random-effect meta-analyses were performed to estimate adverse cardiovascular reaction risks. Quality of evidence was assessed using GRADE. In total, forty-four studies (thirty-six RCTs and eight NRS) satisfied our inclusion criteria. A single RCT found no significant difference in the risk of heart failure with ropinirole compared with bromocriptine (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.07 to 2.04; low certainty). Conversely, three case–control studies reported a risk of heart failure with non-ergot DA treatment. The quality of evidence for the risk of heart failure was judged as low or very low. Findings suggest that non-ergot DA use may be associated with adverse cardiovascular outcomes, including heart failure. Studies are needed to better understand cardiovascular risks associated with PD treatment. - Fuente
- Brain Sciences, vol. 14, n. 8, art. 776
- Materia
-
ENFERMEDAD DE PARKINSON
INSUFICIENCIA CARDIACA
DOPAMINA
AGONISTAS - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/4.0/
- Repositorio
.jpg)
- Institución
- Pontificia Universidad Católica Argentina
- OAI Identificador
- oai:ucacris:123456789/22055
Ver los metadatos del registro completo
| id |
RIUCA_8f322500ff559ac6b244937d2b89cc5c |
|---|---|
| oai_identifier_str |
oai:ucacris:123456789/22055 |
| network_acronym_str |
RIUCA |
| repository_id_str |
2585 |
| network_name_str |
Repositorio Institucional (UCA) |
| spelling |
Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson’s diseaseCrispo, James A. G.Farhat, NawalFortin, YannickPérez Lloret, SantiagoSikora, LindseyMorgan, Rebecca L.Habash, MaraGogna, PriyankaShannon E. KellyElliott, JesseKohen, Dafna E.Bjerre, Lise M.Mattison, Donald R.Hessian, Renée C.Willis, Allison W.Krewski, DanielENFERMEDAD DE PARKINSONINSUFICIENCIA CARDIACADOPAMINAAGONISTASFil: Crispo, James A. G. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; CanadáFil: Farhat, Nawal. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; CanadáFil: Fortin, Yannick. University of Ottawa. McLaughlin Centre for Population Health Risk Assessment; CanadáFil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina. Observatorio de Salud Publica; ArgentinaFil: Sikora, Lindsey. University of Ottawa. Health Sciences Library; CanadáFil: Morgan, Rebecca L. McMaster University. Department of Health Research Methods, Evidence, and Impact; CanadáFil: Habash, Mara. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; CanadáFil: Gogna, Priyanka. Queen's University. Department of Public Health Sciences; CanadáFil: Kelly, Shannon E. University of Ottawa. Faculty of Medicine; Canadá.Fil: Elliott, Jesse. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; CanadáFil: Kohen, Dafna E. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; CanadáFil: Bjerre, Lise M. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; CanadáFil: Mattison, Donald R. Risk Sciences International; CanadáFil: Hessian, Renée C. University of Ottawa. University of Ottawa Heart Institute; CanadáFil: Willis, Allison W. University of Pennsylvania. Perelman School of Medicine. Department of Neurology; Estados UnidosFil: Krewski, Daniel. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; CanadáReports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson’s disease (PD). The objectives of our review were to evaluate the risk of heart failure and other adverse cardiovascular reactions in PD patients who received a non-ergot DA compared with other anti-PD pharmacological interventions, placebo, or no intervention. Studies were identified via searches of six bibliographic databases. Randomized controlled trials (RCTs) and non-randomized studies (NRS) were eligible for study inclusion. Random-effect meta-analyses were performed to estimate adverse cardiovascular reaction risks. Quality of evidence was assessed using GRADE. In total, forty-four studies (thirty-six RCTs and eight NRS) satisfied our inclusion criteria. A single RCT found no significant difference in the risk of heart failure with ropinirole compared with bromocriptine (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.07 to 2.04; low certainty). Conversely, three case–control studies reported a risk of heart failure with non-ergot DA treatment. The quality of evidence for the risk of heart failure was judged as low or very low. Findings suggest that non-ergot DA use may be associated with adverse cardiovascular outcomes, including heart failure. Studies are needed to better understand cardiovascular risks associated with PD treatment.MDPI2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://repositorio.uca.edu.ar/handle/123456789/220552076-342510.3390/brainsci14080776Brain Sciences, vol. 14, n. 8, art. 776reponame:Repositorio Institucional (UCA)instname:Pontificia Universidad Católica Argentinaenginfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/2026-09-28T11:10:45Zoai:ucacris:123456789/22055instacron:UCAInstitucionalhttps://repositorio.uca.edu.ar/Universidad privadaNo correspondehttps://repositorio.uca.edu.ar/oaiclaudia_fernandez@uca.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:25852026-09-28 11:10:46.246Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentinafalse |
| dc.title.none.fl_str_mv |
Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson’s disease |
| title |
Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson’s disease |
| spellingShingle |
Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson’s disease Crispo, James A. G. ENFERMEDAD DE PARKINSON INSUFICIENCIA CARDIACA DOPAMINA AGONISTAS |
| title_short |
Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson’s disease |
| title_full |
Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson’s disease |
| title_fullStr |
Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson’s disease |
| title_full_unstemmed |
Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson’s disease |
| title_sort |
Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson’s disease |
| dc.creator.none.fl_str_mv |
Crispo, James A. G. Farhat, Nawal Fortin, Yannick Pérez Lloret, Santiago Sikora, Lindsey Morgan, Rebecca L. Habash, Mara Gogna, Priyanka Shannon E. Kelly Elliott, Jesse Kohen, Dafna E. Bjerre, Lise M. Mattison, Donald R. Hessian, Renée C. Willis, Allison W. Krewski, Daniel |
| author |
Crispo, James A. G. |
| author_facet |
Crispo, James A. G. Farhat, Nawal Fortin, Yannick Pérez Lloret, Santiago Sikora, Lindsey Morgan, Rebecca L. Habash, Mara Gogna, Priyanka Shannon E. Kelly Elliott, Jesse Kohen, Dafna E. Bjerre, Lise M. Mattison, Donald R. Hessian, Renée C. Willis, Allison W. Krewski, Daniel |
| author_role |
author |
| author2 |
Farhat, Nawal Fortin, Yannick Pérez Lloret, Santiago Sikora, Lindsey Morgan, Rebecca L. Habash, Mara Gogna, Priyanka Shannon E. Kelly Elliott, Jesse Kohen, Dafna E. Bjerre, Lise M. Mattison, Donald R. Hessian, Renée C. Willis, Allison W. Krewski, Daniel |
| author2_role |
author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
ENFERMEDAD DE PARKINSON INSUFICIENCIA CARDIACA DOPAMINA AGONISTAS |
| topic |
ENFERMEDAD DE PARKINSON INSUFICIENCIA CARDIACA DOPAMINA AGONISTAS |
| dc.description.none.fl_txt_mv |
Fil: Crispo, James A. G. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; Canadá Fil: Farhat, Nawal. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; Canadá Fil: Fortin, Yannick. University of Ottawa. McLaughlin Centre for Population Health Risk Assessment; Canadá Fil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina. Observatorio de Salud Publica; Argentina Fil: Sikora, Lindsey. University of Ottawa. Health Sciences Library; Canadá Fil: Morgan, Rebecca L. McMaster University. Department of Health Research Methods, Evidence, and Impact; Canadá Fil: Habash, Mara. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; Canadá Fil: Gogna, Priyanka. Queen's University. Department of Public Health Sciences; Canadá Fil: Kelly, Shannon E. University of Ottawa. Faculty of Medicine; Canadá. Fil: Elliott, Jesse. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; Canadá Fil: Kohen, Dafna E. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; Canadá Fil: Bjerre, Lise M. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; Canadá Fil: Mattison, Donald R. Risk Sciences International; Canadá Fil: Hessian, Renée C. University of Ottawa. University of Ottawa Heart Institute; Canadá Fil: Willis, Allison W. University of Pennsylvania. Perelman School of Medicine. Department of Neurology; Estados Unidos Fil: Krewski, Daniel. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; Canadá Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson’s disease (PD). The objectives of our review were to evaluate the risk of heart failure and other adverse cardiovascular reactions in PD patients who received a non-ergot DA compared with other anti-PD pharmacological interventions, placebo, or no intervention. Studies were identified via searches of six bibliographic databases. Randomized controlled trials (RCTs) and non-randomized studies (NRS) were eligible for study inclusion. Random-effect meta-analyses were performed to estimate adverse cardiovascular reaction risks. Quality of evidence was assessed using GRADE. In total, forty-four studies (thirty-six RCTs and eight NRS) satisfied our inclusion criteria. A single RCT found no significant difference in the risk of heart failure with ropinirole compared with bromocriptine (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.07 to 2.04; low certainty). Conversely, three case–control studies reported a risk of heart failure with non-ergot DA treatment. The quality of evidence for the risk of heart failure was judged as low or very low. Findings suggest that non-ergot DA use may be associated with adverse cardiovascular outcomes, including heart failure. Studies are needed to better understand cardiovascular risks associated with PD treatment. |
| description |
Fil: Crispo, James A. G. University of Ottawa. Faculty of Medicine. School of Epidemiology and Public Health; Canadá |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://repositorio.uca.edu.ar/handle/123456789/22055 2076-3425 10.3390/brainsci14080776 |
| url |
https://repositorio.uca.edu.ar/handle/123456789/22055 |
| identifier_str_mv |
2076-3425 10.3390/brainsci14080776 |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/4.0/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/4.0/ |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
MDPI |
| publisher.none.fl_str_mv |
MDPI |
| dc.source.none.fl_str_mv |
Brain Sciences, vol. 14, n. 8, art. 776 reponame:Repositorio Institucional (UCA) instname:Pontificia Universidad Católica Argentina |
| reponame_str |
Repositorio Institucional (UCA) |
| collection |
Repositorio Institucional (UCA) |
| instname_str |
Pontificia Universidad Católica Argentina |
| repository.name.fl_str_mv |
Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentina |
| repository.mail.fl_str_mv |
claudia_fernandez@uca.edu.ar |
| _version_ |
1877586772208123904 |
| score |
13.265058 |